Caution Needed in Prescribing IBD Meds in CKD
Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional therapies, including immunomodulators and aminosalicylates, as well as with JAK inhibitors.
METHODOLOGY:
From 4%-23% of patients with IBD also have renal disease, which can affect how the body processes medications; however, little data is available to guide physicians in choosing safe and effective IBD treatments for patients with advanced CKD.
Researchers conducted a review of studies about IBD treatments in the setting of CKD by searching MEDLINE and EMBASE through March 31, 2025, using relevant keywords.
IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators (such as thiopurines and methotrexate), calcineurin inhibitors, biologics (such as monoclonal antibodies against tumor necrosis factors (anti-TNFs), integrin receptors, and interleukins), and small molecules (such as JAK inhibitors and sphingosine-1-phosphate [S1P] receptor modulators).
TAKEAWAY:
Corticosteroids in advanced kidney disease, including in patients requiring dialysis, do not require dosage adjustment. Budesonide is preferred over prednisolone, and corticosteroids are typically administered at the lowest effective dose for the shortest duration.
Mesalazine, an aminosalicylate, can trigger acute interstitial nephritis; the immunomodulator methotrexate, even at 2-4 mg/wk, may cause irreversible renal decline, profound myelosuppression, and higher mortality in patients with end-stage kidney disease on hemodialysis; and calcineurin inhibitors can be nephrotoxic by reducing renal blood flow and glomerular filtration rate.
Monoclonal antibodies, including anti-TNF, anti-integrin, and anti-interleukin 12/23 therapies, demonstrated safety in renal insufficiency and hemodialysis.
For JAK inhibitors and thiopurines, dose adjustments were recommended in advanced renal disease, whereas S1P receptor modulators could be used in CKD without any dose adjustments.
IN PRACTICE:
'Selecting appropriate therapeutics for managing IBD in patients with CKD necessitates a tailored approach, emphasizing diligent surveillance of renal function to optimize treatment efficacy and minimize renal compromise. Dose adjustments of IBD therapeutics are not required for patients with stage I or II CKD. Depending on specific drug metabolism and renal excretion, dose adjustments may be required at more advanced-stage CKD,' the authors wrote.
SOURCE:
The study, led by Lynna Chen, Eastern Health Clinical School, Monash University in Melbourne, Australia, was published online in Alimentary Pharmacology & Therapeutics.
LIMITATIONS:
This review did not discuss limitations.
DISCLOSURES:
The authors received no specific funding for this work. Two authors disclosed receiving advisory fees and serving as speakers for various pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
a day ago
- New York Post
Just one can of diet soda can increases this health risk, new study shows
If you're the type of person to crack open a diet soft drink at 3 p.m. when you're looking for a pick-me-up without the calories, a new study says that this daily habit might be doing more harm than you think. New Australian research has found that knocking back just one artificially sweetened soft drink a day, like Diet Coke, Pepsi Max or Zero Sugar Solo, may increase your risk of developing type 2 diabetes by a staggering 38%. Advertisement Surprisingly, that's an even higher risk than those opting for classic full-sugar options, which were linked to a 23% rise. 4 New research found that knocking back just one artificially sweetened soft drink a day may increase your risk of developing type 2 diabetes. Pormezz – Professor Barbora de Courten, senior author on the study, told that the findings signal a need to rethink current public health strategies. 'It might be time to broaden the policy discussion not just about taxing sugar, but about reducing population-level intake of all harmful beverages, regardless of whether they're sweetened with sugar or synthetic alternatives,' said Professor de Courten, who is also a specialist physician at the Department of Diabetes & Vascular Medicine. Sugar, artificial beverages, and type 2 diabetes Advertisement 4 Professor Barbora de Courten said that the findings signal a need to rethink current public health strategies. Parilov – The longitudinal study, conducted by a team from Monash University, RMIT University and the Cancer Council Victoria, followed more than 36,000 Australian adults over nearly 14 years. 'Drinking one or more of these beverages each day – whether sweetened with sugar or artificial substitutes – was linked to a significantly higher chance of developing type 2 diabetes,' said Mr Hussen Kabthymer, who was involved in the study. Professor de Courten said the findings challenge the common belief that artificially sweetened drinks are a better option. Advertisement 4 Professor de Courten said the findings challenge the common belief that artificially sweetened drinks are a better option. – 'Artificial sweeteners often recommended to people at risk of diabetes as a healthier alternative, but our results suggest they may pose their own health risks,' she said. While the connection between sugary drinks and diabetes could mostly be explained by obesity, the connection between diet soft drinks and type 2 diabetes stayed strong even after factoring in body weight, suggesting that these drinks might directly affect how our metabolism works. 'The study, which involved participants aged 40–69 years, also adjusted for other lifestyle factors such as diet, exercise, education, and health history. What is type 2 diabetes? Advertisement 4 Type 2 diabetes is a chronic condition where the body either can't properly use insulin or doesn't produce enough of it, causing blood sugar levels to rise. Mdv Edwards – Type 2 diabetes impacts about 1.3 million Australians and over 500 million people globally, with most cases related to diet and lifestyle. It is a chronic condition where the body either can't properly use insulin or doesn't produce enough of it, causing blood sugar levels to rise. According to Diabetes Australia, it usually develops in adults over 45, but is increasingly occurring in younger age groups. Over time, uncontrolled type 2 diabetes can damage the eyes, kidneys, nerves and heart, and lead to serious complications like kidney failure, vision loss and heart disease.
Medscape
a day ago
- Medscape
Patients With IBD and PSC Face Elevated CRC Risk
TOPLINE: Patients with inflammatory bowel disease (IBD), especially those who had been diagnosed before 20 years of age, and with primary sclerosing cholangitis (PSC) had an elevated risk for colorectal cancer (CRC). METHODOLOGY: Researchers conducted a cohort study to analyse the effect of IBD with and without PSC on the risk for CRC. They enrolled patients with IBD diagnosed between January 1969 and December 2014 from the Swedish National Patient Register, including those who underwent colectomy. Patients were classified as those having PSC on the basis of the diagnosis of cholangitis. A total of 85,813 patients with IBD alone and 3066 with IBD and concomitant PSC were included. Each patient with IBD was matched with five control individuals from the general population without IBD (n = 432,037). Information on the diagnosis of CRC and cause of death was obtained using register data. Synchronous cancer was defined as two or more CRCs occurring within or less than 180 days. TAKEAWAY: Patients with IBD and concomitant PSC and those without PSC had an increased risk for CRC (incidence rate [IR], 269 and 95 cases per 100,000 person-years, respectively) compared with matched control individuals (IR, 58 cases per 100,000 person-years; P < .001). Those with unclassified IBD and PSC had the highest risk for CRC (IR ratio [IRR], 7.38; 95% CI, 5.56-9.63). Compared with control individuals, patients diagnosed with IBD before the age of 20 years, with or without PSC, demonstrated a significantly elevated risk for CRC (IRR, 74.97 and 18.75, respectively; P < .001). CRC was more likely to be in the proximal colon among patients with IBD and PSC than among those with IBD without PSC and control individuals, with 37.5% vs 27% and 22.4% of CRC being located in the caecum and ascending colon. Synchronous cancers were found in 4.7% of patients with IBD and PSC and 4.4% of those with IBD without PSC vs 1.9% of control individuals (P < .001). Those with IBD and PSC had the highest mortality (adjusted hazard ratio, 2.56; P < .001). IN PRACTICE: "In PSC+ [IBD with a concomitant PSC diagnosis], primary CRC is more often located in the proximal colon. This must be considered when counselling patients with IBD regarding type of resection for cancer and choice of restorative surgery," the authors of the study wrote. SOURCE: This study was led by Maie Abdalla, MD, PhD, Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. It was published online on July 22, 2025, in Clinical Gastroenterology and Hepatology. LIMITATIONS: The register included only hospital discharge diagnoses before 2001, potentially missing outpatients with milder disease. Variables such as diet, smoking, family history of CRC, colitis severity, tumour stage, and others could not be accounted for. PSC lacks a specific International Classification of Diseases code; therefore, researchers had to combine a cholangitis code with an IBD diagnosis to identify cases. DISCLOSURES: This study was supported by the Medical Research Council of Southeast Sweden and by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement, Sweden. One author reported being an employee of AstraZeneca and having shares in the same. The author also reported receiving prior research funding and honoraria for lectures and consultancy from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
